Propanc Biopharma (PPCB) Q1 2026 earnings summary

Executive summary

• No revenue was generated as the company remains in the R&D phase for its lead cancer treatment candidate, PRP, with ongoing collaborations and patent activity in major jurisdictions.

• Advanced PRP toward a Phase 1b clinical trial for advanced solid tumors, with manufacturing and regulatory preparations underway.

• Progressed Rec-PRP synthetic program for improved stability and scalability, with preclinical development planned.

• Completed a $4 million public offering in August 2025, resulting in a Nasdaq listing and net proceeds of $3.3 million after expenses.

• Entered a $100 million private placement facility, receiving an initial $1 million tranche.

Financial highlights

• Total assets as of September 30, 2025, were $17.98 million, down from $19.63 million at June 30, 2025.

• Total current assets at quarter-end were $8.76 million, up from $8.35 million at June 30, 2025.

• Cash balance increased to $602,737 from $12,088 at the prior quarter-end, primarily due to the equity raise.

• Current liabilities decreased to $3.45 million from $5.58 million, reflecting repayments and conversions of debt.

• Net loss for Q1 2026 was $4.84 million, a significant increase from $0.35 million in Q1 2025, driven by higher stock-based consulting expenses and administrative costs.

Outlook and guidance

• The company continues to seek additional funding to support ongoing R&D and operational activities.

• Financing facility expected to support R&D activities, including PRP and Rec-PRP advancement.

• Focus remains on initiating Phase 1b PRP clinical trial and expanding the intellectual property portfolio.

• Management is negotiating with lenders to extend maturity dates on past-due convertible debt.

• Further research collaborations are under negotiation, contingent on available working capital.